Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + golidocitinib + selinexor
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This triplet combination therapy consists of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody; golidocitinib, a potent and selective Janus kinase 1 (JAK1) inhibitor; and selinexor, a first-in-class selective inhibitor of nuclear export (SINE) targeting XPO1. The regimen is currently being evaluated in a Phase Ib/II clinical trial sponsored by Fudan University for the treatment of relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). By simultaneously blocking the PD-1/PD-L1 immune checkpoint, inhibiting the dysregulated JAK/STAT signaling pathway, and restoring the nuclear localization of tumor suppressor proteins via XPO1 inhibition, this combination aims to provide a synergistic therapeutic effect in patients who have progressed after standard L-asparaginase-containing chemotherapy.
- Brand names
- TevimbraXpovioGaoledai
- Other names
- tislezumabtislelizumabgolidocitinibselinexor
02
Targets
Beyond the preview
Go deeper on tislelizumab + golidocitinib + selinexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + golidocitinib + selinexor.